-
CTI 2024丨Prof. Xi Zhang: New Developments and Challenges in Chronic Graft-Versus-Host Disease
From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) took place in Hangzhou, China, bringing together global leaders in cellular and immune therapies. This prestigious event served as a platform for academic exchange and a showcase for cutting-edge research in the field. During the conference, Prof. Xi Zhang from the Department…
-
How I Treat丨Prof. Fengkui Zhang: My Approach to Treating Severe Aplastic Anemia
Severe aplastic anemia (AA) remains a significant therapeutic challenge despite progress in its diagnosis and treatment. Issues such as difficulty in donor matching, side effects of immunosuppressive therapy (IST), and suboptimal hematologic responses demand continued exploration of innovative solutions. Prof. Fengkui Zhang of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical…
-
2024 Great Wall Hematology Forum丨Prof. Wenming Chen: Integrating Fundamentals and Clinical Practice to Foster Young Talent
On November 15–16, 2024, the “Annual Meeting of the Hematology Committee of the Chinese Medical Education Association—Great Wall Hematology Forum” was successfully held in Beijing. This conference brought together leading experts in hematology to discuss advancements in the diagnosis and treatment of hematological diseases, delve into the latest research findings, and explore the future direction…
-
SIBCS 2024 | A Sneak Peek at Key Updates in the 2025 Edition of the “CBCS Little Red Book” from Top Experts
The expert voting on key issues for the 2025 edition of the Guidelines and Standards for Breast Cancer Diagnosis and Treatment (Essential Version), also known as the CBCS Little Red Book, organized by the Chinese Anti-Cancer Association and the Chinese Medical Association’s Oncology Branch, has concluded. The new version is on the horizon! Oncology Frontier…
-
Dr.Hong You and Dr.Wei Chen’s Team Proliferative T Cell Subpopulations in the Liver Promote Fibrosis Reversal in CHB Patients After Antiviral Therapy
Research Background and Objectives CHB liver fibrosis is a pathological condition resulting from imbalanced extracellular matrix deposition due to HBV-induced liver damage and repair. This condition can progress to cirrhosis…
-
AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure
Study 1: Personalized Nutritional Support for HBV-ACLF Patients at Nutritional Risk: Preliminary Findings from a Randomized Controlled Trial Authors: Zhipeng Li, Peipei Wang, Wenxiong Xu, Chan Xie, Liang Peng Malnutrition…
-
AASLD 2024 | Nadege Pelletier: Exploring new hope for innovative immunotherapy for chronic hepatitis B
Hepatology Digest: Thank you for joining us. Could you start by introducing yourself and sharing the focus of Barinthus Biotherapeutics? Nadege Pelletier: Of course, thank you. My name is Nadege…
-
Dr. Hua Zhong and Dr. Baohui Han: Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients
Modern advancements in oncology have introduced various breakthrough treatment options for lung cancer, which is now one of the most rapidly evolving solid tumors. To help clinicians stay updated on key advancements in this field, Oncology Frontier has partnered with Dr. Hua Zhong and Dr. Baohui Han of the Department of Respiratory and Critical Care…
Connecting Medical Expertise through Media